Date: 2015-05-19
Type of information: Financing round
Company: Anagenesis Biotechnologies (France)
Investors: Cap Innov’Est (France)
Amount: undisclosed
Funding type: financing round
Planned used: This funding will enable Anagenesis Biotechnologies to expand and complete the “Proof of Concept” that targeting the adult muscle stem cells, called satellite cells, is able to regenerate muscle fibers.
Others: * On May 19th, 2015, Anagenesis Biotechnologies, a biotechnology company developing therapies for Duchenne Muscular Dystrophy (DMD) and other muscle diseases, announced the investment of Cap Innov’Est, an interregional-based seed fund. The company develops new treatments against muscle diseases such as Duchenne muscular dystrophy, sarcopenia and cachexia. Jean-François Rax, Investment Director at Cap Innov’Est, will join the Board of Anagenesis Biotechnologies composed of Dr Christopher Henderson, VP, Neurology, Biogen, co-founder of Anagenesis Biotechnologies and Trophos (recently acquired by Roche), Nicolas Carboni, President and CEO of SATT Conectus, Philippe Grand, Partner, Ernst & Young and Dr Jean-Yves Bonnefoy, Chairman.
Therapeutic area: Neuromuscular diseases - Regenerative medicine
